Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension.
Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension.
复制标题
DOI：
10.21542/gcsp.2018.14
复制
发表时间：
2018-06-30
期刊：
影响因子：
--
通讯作者：
Miller E
中科院分区：
文献类型：
--
作者：
Ahmed M;Miller E
巨噬细胞移动抑制因子（MIF）已被描述为促炎细胞因子和神经内分泌功能的调节剂。它通过促进其他炎性细胞因子如TNF-α和IL-6的释放，最终引发慢性炎性免疫应答，在炎症级联反应中发挥重要的上游作用。由于肺可以合成和释放MIF，许多研究已经研究了MIF作为评估肺动脉高压（PAH）患者的生物标志物以及使用抗MIF作为PAH的新治疗方式的潜在作用。
Macrophage migration inhibitory factor (MIF) has been described as a pro-inflammatory cytokine and regulator of neuro-endocrine function. It plays an important upstream role in the inflammatory cascade by promoting the release of other inflammatory cytokines such as TNF-alpha and IL-6, ultimately triggering a chronic inflammatory immune response. As lungs can synthesize and release MIF, many studies have investigated the potential role of MIF as a biomarker in assessment of patients with pulmonary arterial hypertension (PAH) and using anti-MIFs as a new therapeutic modality for PAH.